EpiCypher Inc.

Home
United States
Durham, NC
EpiCypher Inc.

EpiCypher is a bioscience company developing unique reagents and services for chromatin biology and epigenetics research.

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Our technologies and products are making studies possible that were not imaginable just a few years ago. Our innovation is a direct result of the scientific power associated with EpiCypher. Our renowned chromatin researchers possess expertise and unique insight into epigenetics that benefit our customers in ways other companies cannot. Arising from an abundance of demand for high quality products from the laboratories of Mark Bedford, Brian Strahl, and Or Gozani EpiCypher was founded on January 18, 2012 as a spin-out from University of North Carolina at Chapel Hill. Starting with the groundbreaking and proprietary histone peptide array platform, EpiGold™, EpiCypher has developed a wide portfolio of best in class products. EpiCypher's mission is to develop products to enable researchers to complete experiments that are not otherwise possible.

04/01/2026

‼️ REMINDER: Our next webinar is one week away! ‼️

📢 Fiber-seq is changing how we study gene regulation in crops.

Join us for a live webinar with guest speaker Dr. Christine Queitsch (University of Washington School of Medicine, Seattle) to learn about how her lab has applied Fiber-seq to maize — revealing regulatory complexity that short-read methods simply cannot access.

👉 Learn More & Register Here:
https://app.livestorm.co/epicypher/resolving-the-complexity-of-crop-gene-regulation-with-fiber-seq

03/31/2026

Understanding epigenetic drivers of cancer starts with reliable tools.

Introducing the H3K36me2 CUTANA™ CUT&RUN and CUT&Tag Antibody, validated for specificity and performance using SNAP-CUTANA controls and knockout models. This antibody supports translational research, including studies on NSD2-driven oncogenic programs.

Learn more: https://www.epicypher.com/product/h3k36me2-cutana-cutrun-and-cuttag-antibody/
🔬

03/30/2026

When gene regulation is part of the drug mechanism of action, confidence comes from measuring it directly. 🧬🔬

Fiber-seq provides an integrated view of gene regulation on DNA by capturing chromatin accessibility, DNA methylation, and protein footprints together on single molecules. For programs targeting DNA-binding proteins, this means mechanistic confidence grounded in direct measurement — linking protein occupancy footprints to DNA methylation and chromatin accessibility on the same molecule, rather than inferring relationships across separate assays.

With EpiCypher’s end-to-end Fiber-seq services, you send samples and receive high-quality datasets with preliminary analysis, with follow-up assays available depending on the project to support downstream validation as programs mature.

Learn more about EpiCypher’s Fiber-seq end-to-end services: https://www.epicypher.com/services/cutana-fiber-seq-assay-services/

03/27/2026

Customer Talk Spotlight

At the ABRF Annual Meeting (March 28 to 31), Drew Hankiewicz, Genomics Core Associate at the Van Andel Institute, will present “Implementing Fiber-seq into a Core Lab.”

In this talk, Drew will discuss what it took to successfully implement Fiber-seq in a genomics core that does not typically work with live cells or nuclei, sharing insights that may help other facilities evaluating new sequencing technologies.

📅 March 29
⏰ 12:25 PM ET

We are excited to see researchers using Fiber-seq to expand capabilities in core facilities.

03/25/2026

📢 Fiber-seq is changing how we study gene regulation in crops.

Join us for a live webinar with guest speaker Dr. Christine Queitsch (University of Washington School of Medicine, Seattle) to learn about how her lab has applied Fiber-seq to maize — revealing regulatory complexity that short-read methods simply cannot access.

👉 Learn More & Register Here:
https://app.livestorm.co/epicypher/resolving-the-complexity-of-crop-gene-regulation-with-fiber-seq

03/24/2026

We’re excited to be presenting at CSHL: The PARP Family and ADP-ribosylation!

Join Lu Sun, PhD, Associate Director of Product Development at EpiCypher, for the poster:
“Novel biochemical tools to study histone ADP-ribosylation signaling”

📍 Poster Session
🗓 Thursday, March 26
⏰ 8:00–10:30 PM

Learn how EpiCypher is advancing the study of chromatin ADP-ribosylation using fully defined nucleosome substrates and multiplexed screening with Captify® Luminex. This work highlights the importance of physiologically relevant systems for understanding DNA damage signaling and chromatin biology.

We’ll also be previewing our upcoming ADP-ribosylated nucleosomes (launching Q2), along with our EpiDyne® and Captify® platforms.

📥 Download the poster here:
https://explore.epicypher.com/posters/CSHL26/histone-ADP-ribosylation-signaling

We hope to see you there!

03/20/2026

We’re proud to sponsor the upcoming Fragile Nucleosome seminar featuring Sunil Kumar Pradhan and Genevieve Fourel 🔬

This session will highlight new research on chromatin dynamics, heterochromatin regulation, and genome organization, offering valuable insights for scientists working in epigenetics.

📅 March 25 at 9am PDT
Register here: https://us06web.zoom.us/webinar/register/WN_i4n53UTdQLO8okWVfykxJQ

03/18/2026

🔬💡 Research Spotlight: Reversing drug resistance in prostate cancer by targeting epigenetic plasticity.

A powerful study in Nature demonstrates that targeting the histone methyltransferase NSD2 can reverse lineage plasticity in advanced prostate cancer. EpiCypher’s pAG-Tn5 (15-1017) was critical in the CUT&Tag profiling, enabling the investigation of epigenetic mechanisms that promote lineage plasticity.

Key take aways:

✅ Organoid models recapitulate the molecular heterogeneity of castration-resistant prostate cancer (CRPC) and demonstrate the shift from androgen receptor (AR) positive mesenchymal to a neuroendocrine (NE) state.

✅ NSD2, a histone methyltransferase that deposits H3K36me2, is elevated in CRPC-NE and its activity promotes lineage plasticity with neuroendocrine differentiation and poor clinical outcomes.

✅ Pharmacological or CRISPR-mediated targeting of NSD2 leads to plasticity reversal and restores sensitivity to an AR inhibitor enzalutamide.

🔗 Read More: https://www.nature.com/articles/s41586-025-09727-z

03/17/2026

🍀 Feeling lucky this St. Patrick’s Day?

At EpiCypher, we know great science isn’t luck — it’s built on the right reagents, assays, and expertise.

Whether you're exploring chromatin biology, screening epigenetic targets, or validating antibodies, our services help turn discoveries into breakthroughs.

Here’s to a little luck and a lot of good science. Happy St. Patrick’s Day! 🧬🍀

03/12/2026

Adopting a new assay is always a risk. Building in-house expertise takes time.

EpiCypher’s Fiber-seq Services can help you accelerate your research by building a robust, long-term assay expertise. Your team will run Fiber-seq experiments with our expert helping you troubleshoot and optimize your assay. Accomplish your first successful Fiber-seq run, your first high-quality dataset, and your first round of analysis quickly and painlessly!

EpiCypher’s Fiber-seq Services team will help you setup your experiment, dial in nuclei purification, troubleshoot early runs, and process your data, so you can achieve your research milestones with confidence. 🔬🧬

Learn more about Fiber-seq Services: https://www.epicypher.com/services/cutana-fiber-seq-assay-services/

03/11/2026

Looking for a faster, more efficient alternative to ChIP-seq?

Our CUTANA™ CUT&Tag Assays are built for high-throughput chromatin profiling — delivering faster workflows, lower sequencing costs, and higher signal-to-noise than traditional ChIP-seq.

✨ Now even better with new updates:
• NEW 24-reaction kit option
• $300 price drop on the 48-reaction kit
• Workflow improvements for more consistent results, even with challenging targets

Explore the updated assays:
https://www.epicypher.com/product/cutana-cuttag-kit/

03/10/2026

🔬💡Research Spotlight: EpiCypher’s CUTANA™ CUT&RUN (14-1048) and BRD4 antibody (13-2003) were used as powerful chromatin profiling tools in a new study in Science Translational Medicine. The authors map the chromatin landscape in a highly aggressive pediatric brain tumor and identify a compelling combination therapeutic strategy.

Key take aways:

✅ BRD4 and FACT subunits are overexpressed and co-localize at developmental gene loci in Diffuse Midline Glioma (DMG). Combinatorial inhibition produced stronger anti-tumor effects than targeting either pathway alone.

✅ Dual inhibition of FACT and BRD4 alters the splicing landscape, increases chromatin compaction at key oncogenes, and triggers an immune infiltration response within tumors.

✅ Combined targeting significantly reduced tumor burden in vivo, highlighting a therapeutic strategy that exploits the epigenetic dependency of DMG, an aggressive brain tumor with limited treatment options.

🔗 Check out the article here: https://www.science.org/doi/10.1126/scitranslmed.adr1557

Looking to uncover similar chromatin-dependent vulnerabilities, explore the reagents and workflows that support discoveries like this? Visit our website to learn more!
👉epicypher.com

Address

6 Davis Drive
Durham, NC
27709

Telephone

+18553742461

Website

http://www.epicypher.com/

Alerts

Be the first to know and let us send you an email when EpiCypher Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to EpiCypher Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in Durham?